Pharmacies sue GoodRx and PBMs over ‘illegal’ reimbursement fees

Taking stock of the drug industry, from the lab to the medicine chest

November 5, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Pharmacies sue GoodRx and PBMs over 'illegal' reimbursement fees Mounting clashes over such fees are at the heart of what independent pharmacies have labeled a growing crisis that affects consumer choice. By Ed Silverman STAT+ | 7 companies to watch in AI protein design Latest installment in STAT's Who to Know series looks at startups using AI to design proteins: Absci, Xaira, BigHat, Profluent, Fable, Nabla, and Generate. By Brittany Trang STAT+ | Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment Company says preparatory chemotherapy 'likely caused' death; improvements seen in other trial participants. By Adam Feuerstein and Jason Mast Adobe STAT+ | Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit Newly released early data showed the experimental therapy, anito-cel, resulted in zero cases of delayed neurotoxicity in a clinical trial. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser